The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors
Open accessAbstract
Despite the promising efficacy of immunoregulation in cancer therapy, the clinical benefit has been restricted by inefficient infiltration of lymphocytes in the evolution of immune evasion. Also, immune-related adverse events have often occurred due to the off-target binding of therapeutics to normal tissues after systematic treatment. In light of this, we have developed a synergistic immunotherapy strategy that locally targets the immunoinhibitory receptor programmed cell death protein 1 (PD1) and immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO) for the treatment of melanoma through a microneedle-based transcutaneous delivery approach. The embedded immunotherapeutic nanocapsule loaded with anti-PD1 antibody (aPD1) is assembled from hyaluronic acid modified with 1-methyl-dl-tryptophan (1-MT), an inhibitor of IDO. This formulation method based on the combination strategy of "drug A in carriers formed by incorporation of drug B" facilitates the loading capacity of therapeutics. Moreover, the resulting delivery device elicits the sustained release and enhances retention of checkpoint inhibitors in the tumor microenvironment. Using a B16F10 mouse melanoma model, we demonstrate that this synergistic treatment has achieved potent antitumor efficacy, which is accompanied by enhanced effective T cell immunity as well as reduced immunosuppression in the local site.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Self-assembly of block copolymers
Mai, Y., & Eisenberg, A. (2012) · Chemical Society Reviews · doi:10.1039/c2cs35115c · Cited by 3,610
Prausnitz, M. R., & Langer, R. (2008) · Nature Biotechnology · doi:10.1038/nbt.1504 · Cited by 3,517
Cited by
Delivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
Nanotechnology for Multimodal Synergistic Cancer Therapy
Fan, W., Yung, B., Huang, P., & Chen, X. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00258 · Cited by 1,791
Xu, J., Xu, L., Wang, C., Yang, R., Zhuang, Q., Han, X., Dong, Z., Zhu, W., Peng, R., & Liu, Z. (2017) · ACS Nano · doi:10.1021/acsnano.7b00715 · Cited by 695
Self-citationMakvandi, P., Kirkby, M., Hutton, A. R. J., Shabani, M., Yiu, C. K. Y., Baghbantaraghdari, Z., Jamaledin, R., Carlotti, M., Mazzolai, B., Mattoli, V., et al. (2021) · Nano-Micro Letters · doi:10.1007/s40820-021-00611-9 · Cited by 455
Feng, B., Zhou, F., Hou, B., Wang, D., Wang, T., Fu, Y., Ma, Y., Yu, H., & Li, Y. (2018) · Advanced Materials · doi:10.1002/adma.201803001 · Cited by 451
Recent advances of microneedles for biomedical applications: drug delivery and beyond
Yang, J., Liu, X., Fu, Y., & Song, Y. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.03.007 · Cited by 378
Engineering Magnetosomes for Ferroptosis/Immunomodulation Synergism in Cancer
Zhang, F., Li, F., Lu, G.-H., Nie, W., Zhang, L., Lv, Y., Bao, W., Gao, X., Wei, W., Pu, K., et al. (2019) · ACS Nano · doi:10.1021/acsnano.9b00892 · Cited by 357
Xie, W., Deng, W.-W., Zan, M., Rao, L., Yu, G.-T., Zhu, D.-M., Wu, W.-T., Chen, B., Ji, L.-W., Chen, L., et al. (2019) · ACS Nano · doi:10.1021/acsnano.8b03788 · Cited by 343
Cheng, K., Ding, Y., Zhao, Y., Ye, S., Zhao, X., Zhang, Y., Ji, T., Wu, H., Wang, B., Anderson, G. J., et al. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b01071 · Cited by 325
Advances in transdermal insulin delivery
Zhang, Y., Yu, J., Kahkoska, A. R., Wang, J., Buse, J. B., & Gu, Z. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.12.006 · Cited by 325
Self-citationPolymeric microneedles for transdermal protein delivery
Ye, Y., Yu, J., Wen, D., Kahkoska, A. R., & Gu, Z. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.01.015 · Cited by 324
Self-citationQu, F., Geng, R., Liu, Y., & Zhu, J. (2022) · Theranostics · doi:10.7150/thno.69999 · Cited by 321
Cardiac cell–integrated microneedle patch for treating myocardial infarction
Tang, J., Wang, J., Huang, K., Ye, Y., Su, T., Qiao, L., Hensley, M. T., Caranasos, T. G., Zhang, J., Gu, Z., et al. (2018) · Science Advances · doi:10.1126/sciadv.aat9365 · Cited by 316
Self-citationPhuengkham, H., Ren, L., Shin, I. W., & Lim, Y. T. (2019) · Advanced Materials · doi:10.1002/adma.201803322 · Cited by 306
Delivering safer immunotherapies for cancer
Milling, L., Zhang, Y., & Irvine, D. J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.011 · Cited by 305
Recent Advances in Glucose‐Oxidase‐Based Nanocomposites for Tumor Therapy
Wang, M., Wang, D., Chen, Q., Li, C., Li, Z., & Lin, J. (2019) · Small · doi:10.1002/smll.201903895 · Cited by 302
Molecular and nanoengineering approaches towards activatable cancer immunotherapy
Zhang, C., & Pu, K. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00773c · Cited by 302
Injectable Bioresponsive Gel Depot for Enhanced Immune Checkpoint Blockade
Yu, S., Wang, C., Yu, J., Wang, J., Lu, Y., Zhang, Y., Zhang, X., Hu, Q., Sun, W., He, C., et al. (2018) · Advanced Materials · doi:10.1002/adma.201801527 · Cited by 294
Self-citationLocal biomaterials-assisted cancer immunotherapy to trigger systemic antitumor responses
Chen, Q., Chen, M., & Liu, Z. (2019) · Chemical Society Reviews · doi:10.1039/c9cs00271e · Cited by 288
Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook
Wang, C., Ye, Y., Hu, Q., Bellotti, A., & Gu, Z. (2017) · Advanced Materials · doi:10.1002/adma.201606036 · Cited by 286
Self-citationStimuli-responsive transdermal microneedle patches
Makvandi, P., Jamaledin, R., Chen, G., Baghbantaraghdari, Z., Zare, E. N., Di Natale, C., Onesto, V., Vecchione, R., Lee, J., Tay, F. R., et al. (2021) · Materials Today · doi:10.1016/j.mattod.2021.03.012 · Cited by 283
Self-citationYang, Z., Gao, D., Guo, X., Jin, L., Zheng, J., Wang, Y., Chen, S., Zheng, X., Zeng, L., Guo, M., et al. (2020) · ACS Nano · doi:10.1021/acsnano.0c07721 · Cited by 275
Hyaluronic acid and albumin based nanoparticles for drug delivery
Lei, C., Liu, X.-R., Chen, Q.-B., Li, Y., Zhou, J.-L., Zhou, L.-Y., & Zou, T. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.01.033 · Cited by 266
Engineering nanoparticles to locally activate T cells in the tumor microenvironment
Wang, D., Wang, T., Yu, H., Feng, B., Zhou, L., Zhou, F., Hou, B., Zhang, H., Luo, M., & Li, Y. (2019) · Science Immunology · doi:10.1126/sciimmunol.aau6584 · Cited by 261
Microneedle-mediated transdermal drug delivery for treating diverse skin diseases
Yang, D., Chen, M., Sun, Y., Jin, Y., Lu, C., Pan, X., Quan, G., & Wu, C. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.12.004 · Cited by 259
Macroscale biomaterials strategies for local immunomodulation
Dellacherie, M. O., Seo, B. R., & Mooney, D. J. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0106-3 · Cited by 255
HGF/MET and the Immune System: Relevance for Cancer Immunotherapy
Papaccio, F., Della Corte, C. M., Viscardi, G., Di Liello, R., Esposito, G., Sparano, F., Ciardiello, F., & Morgillo, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113595 · Cited by 110
Delivery Strategies for Immune Checkpoint Blockade
Chen, Q., Wang, C., Chen, G., Hu, Q., & Gu, Z. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800424 · Cited by 90
Self-citation
Metadata
- Authors
- Ye, Y., Wang, J., Hu, Q., Hochu, G. M., Xin, H., Wang, C., & Gu, Z.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2016-09-06
- Volume
- 10
- Issue
- 9
- Pages
- 8956-8963
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W2513541135
- Cited by
- 339
- References
- 41
- FWCI
- 15.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.